India to United States: Gemcitabine Export Trade Route

The India to United States Gemcitabine corridor is one of India's established pharmaceutical export routes, with 66 shipments documented worth a combined $6.0M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 46% of all export value, reflecting the consolidated nature of India's gemcitabine manufacturing sector.

Across 10 active suppliers, the average shipment value stands at $90.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 82% of all shipments, consistent with gemcitabine's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 17.6%, placing it at rank #2 among India's top gemcitabine export destinations globally.

On the import side, key buyers of Indian gemcitabine in United States include MYLAN INSTITUTIONAL INC 2898, MYLAN INSTITUTIONAL INC, XXIZEXXSERXXCE XXMPAXX BV and 14 others. MYLAN INSTITUTIONAL INC 2898 is the single largest importer with 13 shipments valued at $1.5M USD.

India's gemcitabine exports to United States are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 24 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 10 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED — together account for 100% of total trade value on this route. The average shipment value of $90.5K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as gemcitabine inj 38mg/ml 26.3ml 1s myl us and gemcitabine inj. 1g us n+ f000206904, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, MYLAN INSTITUTIONAL INC 2898 is the largest importer with 13 shipments worth $1.5M USD — representing 25% of all gemcitabine imports from India on this route. A total of 17 buyers are active on this corridor.